<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biostax Corp. — News on 6ix</title>
<link>https://6ix.com/company/biostax-corp</link>
<description>Latest news and press releases for Biostax Corp. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 21 Feb 2025 14:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biostax-corp" rel="self" type="application/rss+xml" />
<item>
<title>Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration</title>
<link>https://6ix.com/company/biostax-corp/news/biostax-corp-announces-voluntary-delisting-from-otc-pink-market-and-sec-deregistration</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/biostax-corp-announces-voluntary-delisting-from-otc-pink-market-and-sec-deregistration</guid>
<pubDate>Fri, 21 Feb 2025 14:00:00 GMT</pubDate>
<description>ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BIOX) ("Biostax" or "the Company"), a biopharmaceutical company focused on developing innovative immune restoration therapies, today announced its Board of Directors has approved and the Company intends to proceed with the voluntary delisting of its common stock from the OTC Pink marketplace. This strategic decision follows strong shareholder support, with 76.4% voting in favor of the delisting through a Joint Written Conse</description>
</item>
<item>
<title>Immune Therapeutics, Inc. Provides Shareholder Update on 14A</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-provides-shareholder-update-on-14a</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-provides-shareholder-update-on-14a</guid>
<pubDate>Wed, 15 May 2019 13:49:12 GMT</pubDate>
<description>Immune Therapeutics, Inc. Provides Shareholder Update on 14A.</description>
</item>
<item>
<title>Immune Therapeutics welcomes Kevin Phelps to Board of Directors</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-welcomes-kevin-phelps-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-welcomes-kevin-phelps-to-board-of-directors</guid>
<pubDate>Wed, 09 Jan 2019 18:48:12 GMT</pubDate>
<description>Immune Therapeutics welcomes Kevin Phelps to Board of Directors.</description>
</item>
<item>
<title>Research on Lodonal (“LDN”) for HIV-related GI complications, and Inflammation featured in A&U Magazine</title>
<link>https://6ix.com/company/biostax-corp/news/research-on-lodonal-ldn-for-hiv-related-gi-complications-and-inflammation-featured-in-aandu-magazine</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/research-on-lodonal-ldn-for-hiv-related-gi-complications-and-inflammation-featured-in-aandu-magazine</guid>
<pubDate>Thu, 13 Dec 2018 15:27:12 GMT</pubDate>
<description>Research on Lodonal (“LDN”) for HIV-related GI complications, and Inflammation featured in A&U Magazine.</description>
</item>
<item>
<title>Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-welcomes-amb-jack-brewer-to-the-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-welcomes-amb-jack-brewer-to-the-board-of-directors</guid>
<pubDate>Thu, 06 Sep 2018 13:35:12 GMT</pubDate>
<description>Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors.</description>
</item>
<item>
<title>Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-labeled-as-a-pioneer-in-forbes-article-discussing-booming-pet-care-industry</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-labeled-as-a-pioneer-in-forbes-article-discussing-booming-pet-care-industry</guid>
<pubDate>Wed, 05 Sep 2018 15:20:42 GMT</pubDate>
<description>Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry.</description>
</item>
<item>
<title>Renown HIV specialist Dr. Gary Blick Joins Immune Therapeutics Advisory Board</title>
<link>https://6ix.com/company/biostax-corp/news/renown-hiv-specialist-dr-gary-blick-joins-immune-therapeutics-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/renown-hiv-specialist-dr-gary-blick-joins-immune-therapeutics-advisory-board</guid>
<pubDate>Thu, 23 Aug 2018 13:34:42 GMT</pubDate>
<description>Renown HIV specialist Dr. Gary Blick Joins Immune Therapeutics Advisory Board.</description>
</item>
<item>
<title>Immune Therapeutics Adds Former United States Assistant Surgeon General Dr. Roscoe Moore to Board of Directors</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-adds-former-united-states-assistant-surgeon-general-dr-roscoe-moore-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-adds-former-united-states-assistant-surgeon-general-dr-roscoe-moore-to-board-of-directors</guid>
<pubDate>Tue, 07 Aug 2018 12:04:23 GMT</pubDate>
<description>Immune Therapeutics Adds Former United States Assistant Surgeon General Dr. Roscoe Moore to Board of Directors.</description>
</item>
<item>
<title>Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-announces-publication-of-peer-reviewed-scientific-paper-describing-low-dose-naltrexone-ldn-a-promising-treatment-in-immune-related-diseases-and-cancer-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-announces-publication-of-peer-reviewed-scientific-paper-describing-low-dose-naltrexone-ldn-a-promising-treatment-in-immune-related-diseases-and-cancer-therapies</guid>
<pubDate>Wed, 25 Jul 2018 12:33:23 GMT</pubDate>
<description>Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies.</description>
</item>
<item>
<title>Research on Lodonal for HIV related GI complications featured in Plus Magazine</title>
<link>https://6ix.com/company/biostax-corp/news/research-on-lodonal-for-hiv-related-gi-complications-featured-in-plus-magazine</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/research-on-lodonal-for-hiv-related-gi-complications-featured-in-plus-magazine</guid>
<pubDate>Thu, 19 Jul 2018 12:33:57 GMT</pubDate>
<description>Research on Lodonal for HIV related GI complications featured in Plus Magazine.</description>
</item>
<item>
<title>(CORRECTION) Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States</title>
<link>https://6ix.com/company/biostax-corp/news/correction-immune-therapeutics-acquires-10percent-stake-in-cytocom-obtains-exclusive-rights-to-lodonaltm-for-pets-in-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/correction-immune-therapeutics-acquires-10percent-stake-in-cytocom-obtains-exclusive-rights-to-lodonaltm-for-pets-in-united-states</guid>
<pubDate>Tue, 05 Jun 2018 16:15:11 GMT</pubDate>
<description>(CORRECTION) Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States.</description>
</item>
<item>
<title>Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-acquires-10percent-stake-in-cytocom-obtains-exclusive-rights-to-lodonaltm-for-pets-in-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-acquires-10percent-stake-in-cytocom-obtains-exclusive-rights-to-lodonaltm-for-pets-in-united-states</guid>
<pubDate>Tue, 05 Jun 2018 12:03:37 GMT</pubDate>
<description>Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States.</description>
</item>
<item>
<title>Immune Therapeutics, Inc. Files New Drug Application for Lodonol™ in Kenya to Target HIV Epidemic</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-files-new-drug-application-for-lodonoltm-in-kenya-to-target-hiv-epidemic</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-files-new-drug-application-for-lodonoltm-in-kenya-to-target-hiv-epidemic</guid>
<pubDate>Thu, 26 Apr 2018 12:31:48 GMT</pubDate>
<description>Immune Therapeutics, Inc. Files New Drug Application for Lodonol™ in Kenya to Target HIV Epidemic.</description>
</item>
<item>
<title>Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’s Disease</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-received-minutes-from-fda-meeting-for-lodonaltm-for-the-treatment-for-crohns-disease</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-received-minutes-from-fda-meeting-for-lodonaltm-for-the-treatment-for-crohns-disease</guid>
<pubDate>Mon, 26 Mar 2018 13:36:10 GMT</pubDate>
<description>Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’s Disease.</description>
</item>
<item>
<title>Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-announces-first-sales-and-shipment-of-lodonal-receives-trademark-and-patent-approval-from-federal-republic-of-nigeria</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-announces-first-sales-and-shipment-of-lodonal-receives-trademark-and-patent-approval-from-federal-republic-of-nigeria</guid>
<pubDate>Tue, 20 Feb 2018 13:31:31 GMT</pubDate>
<description>Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria.</description>
</item>
<item>
<title>Immune Therapeutics, Inc. Shareholder Update Letter</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-shareholder-update-letter</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-shareholder-update-letter</guid>
<pubDate>Thu, 30 Nov 2017 14:59:12 GMT</pubDate>
<description>Immune Therapeutics, Inc. Shareholder Update Letter.</description>
</item>
<item>
<title>Immune Therapeutics, Inc. Announces Exclusive Agreement for Sale of Lodonal in Kenya Valued at Over $31 Million</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-announces-exclusive-agreement-for-sale-of-lodonal-in-kenya-valued-at-over-dollar31-million</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-announces-exclusive-agreement-for-sale-of-lodonal-in-kenya-valued-at-over-dollar31-million</guid>
<pubDate>Wed, 06 Sep 2017 13:26:12 GMT</pubDate>
<description>Immune Therapeutics, Inc. Announces Exclusive Agreement for Sale of Lodonal in Kenya Valued at Over $31 Million.</description>
</item>
<item>
<title>Immune Therapeutics, Inc. Announces Exclusive Agreement For Sale Of Lodonal In Kenya Valued At Over $31 Million</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-announces-exclusive-agreement-for-sale-of-lodonal-in-kenya-valued-at-over-dollar31-million-1</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-announces-exclusive-agreement-for-sale-of-lodonal-in-kenya-valued-at-over-dollar31-million-1</guid>
<pubDate>Wed, 06 Sep 2017 12:18:42 GMT</pubDate>
<description>Immune Therapeutics, Inc. Announces Exclusive Agreement For Sale Of Lodonal In Kenya Valued At Over $31 Million.</description>
</item>
<item>
<title>Immune Therapeutics, Inc. Appoints John H. Abeles, M.D. as Chairman and CEO of Company’s Subsidiary, Cytocom, Inc. and as Senior Adviser to Immune Therapeutics, Inc.</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-appoints-john-h-abeles-md-as-chairman-and-ceo-of-companys-subsidiary-cytocom-inc-and-as-senior-adviser-to-immune-therapeutics-inc</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-inc-appoints-john-h-abeles-md-as-chairman-and-ceo-of-companys-subsidiary-cytocom-inc-and-as-senior-adviser-to-immune-therapeutics-inc</guid>
<pubDate>Wed, 23 Aug 2017 13:16:41 GMT</pubDate>
<description>Immune Therapeutics, Inc. Appoints John H. Abeles, M.D. as Chairman and CEO of Company’s Subsidiary, Cytocom, Inc. and as Senior Adviser to Immune Therapeutics, Inc..</description>
</item>
<item>
<title>Immune Therapeutics to Present at the 7th Annual LD Micro Invitational</title>
<link>https://6ix.com/company/biostax-corp/news/immune-therapeutics-to-present-at-the-7th-annual-ld-micro-invitational</link>
<guid isPermaLink="true">https://6ix.com/company/biostax-corp/news/immune-therapeutics-to-present-at-the-7th-annual-ld-micro-invitational</guid>
<pubDate>Mon, 05 Jun 2017 12:45:34 GMT</pubDate>
<description>Immune Therapeutics to Present at the 7th Annual LD Micro Invitational.</description>
</item>
</channel>
</rss>